AURA - Multiplikator P/S Aura Bio

Tandha merek Aura Biosciences Inc (AURA)

The normalized P/S of Aura Biosciences, Inc. (AURA) reflects market value dynamics relative to revenue, while records a new level. Aura Biosciences, Inc. (AURA) brings together elite ophthalmic oncologists, creating the conditions necessary to save patient vision. Testing stability ensures strict control over raw material supplies, and precise biopharmaceutical logistics minimize disruption risks, supporting high profitability across all medical projects.

AURA: Multiplikator P/S Aura Biosciences, Inc. 04.07.2022 - 18.11.2026

Rincian analitis perusahaan Aura Biosciences, Inc. (AURA)

- nilai saham lan prakiraan konsensus rega:
Analisis umum perusahaan:AURA, Aura Biosciences Inc
Produk dadi Aura Corp

The specifics of the biopharmaceutical sector, characterized by the uncertainty of Aura Biosciences, Inc. (AURA) clinical trials, make revenue a rare but critical indicator of business viability. This metric compares market capitalization with actual sales volumes, allowing for an assessment of overvaluation relative to current earnings via the price-to-sales ratio.

Pesaing Aura Biosciences, Inc.

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Candel Therapeutics - Kapitalisasi marang pendapatan|Accuray Inc. (ARAY) - Rega marang dodolan|SELLAS Life Sciences Group, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Rasio rega marang pendapatan|HURA - Koefisien rega marang pendapatan|TARA (Protara Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Fate Therapeutics Inc|Multiplikator P/S WHWK|Multiplikator P/S TScan Therapeutics Inc (TCRX)|Rasio rega marang pendapatan championsoncology.com CSBR|XBIT - Kapitalisasi marang pendapatan|CVM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OSTX (OS Therapies)|RADX: Multiplikator P/S|Artiva Biotherapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|ANL (Adlai Nortye) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd